Kiniksa Pharmaceuticals International, plc Quarterly Operating Income (Loss) in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Kiniksa Pharmaceuticals International, plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q2 2024.
  • Kiniksa Pharmaceuticals International, plc Operating Income (Loss) for the quarter ending June 30, 2024 was -$117K, a 96.3% increase year-over-year.
  • Kiniksa Pharmaceuticals International, plc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$27.5M, a 172% decline year-over-year.
  • Kiniksa Pharmaceuticals International, plc annual Operating Income (Loss) for 2023 was -$25.2M, a 358% decline from 2022.
  • Kiniksa Pharmaceuticals International, plc annual Operating Income (Loss) for 2022 was $9.77M.
  • Kiniksa Pharmaceuticals International, plc annual Operating Income (Loss) for 2021 was -$157M, a 0.46% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$27.5M -$117K +$3.04M +96.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-25
Q1 2024 -$30.5M -$16.5M -$5.35M -47.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q4 2023 -$25.2M $81K -$5.97M -98.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$19.2M -$10.9M -$57.3M -124% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $38.1M -$3.15M +$16.2M +83.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-25
Q1 2023 $21.9M -$11.2M +$12.1M +52% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 $9.77M $6.05M +$42.2M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$32.4M $46.4M +$77.1M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$109M -$19.4M +$21.2M +52.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 -$131M -$23.3M +$26M +52.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$157M -$36.1M +$16.8M +31.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$173M -$30.7M +$12.6M +29% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$186M -$40.6M -$8.7M -27.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$177M -$49.3M -$19.9M -67.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$157M -$52.9M -$20.3M -62.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 -$137M -$43.2M -$12.8M -42% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$124M -$31.9M +$7.43M +18.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$132M -$29.4M +$38.3M +56.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$170M -$32.6M +$11.6M +26.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$182M -$30.4M -$4.29M -16.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$177M -$39.3M -$17.8M -82.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$159M -$67.6M -$51.3M -314% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 -$108M -$44.1M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$26.2M -$9.91M -61% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$21.5M -$10.1M -89% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$16.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 -$16.2M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$11.4M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.